ArticleGenes & diseases2025

Targeting STARD4/EGFR axis inhibits growth and overcomes lenvatinib resistance in hepatocellular carcinoma.

Mengting Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.